CSL broke ground on the expansion of its manufacturing facility in Kankakee, Illinois. The newly expanded facility will increase the company's ability to produce plasma-derived therapies for people living with rare and serious diseases and other acute medical issues while bringing hundreds of new positions to the state.
The Kankakee expansion, expected to be operational by 2031, will incorporate CSL's Horizon 2 manufacturing process, a patented, yield enhancing technology that enables significantly greater production of immunoglobulin from the same base amount of plasma.
Many of the conditions that plasma-derived therapies treat are relatively rare but together, they affect thousands of people, including those living with hemophilia, primary immunodeficiency, and hereditary angioedema (HAE). In addition to treating rare conditions, PDTs are also used as a lifesaving standard of care for many emergency and life-threatening conditions. These include trauma - such as car accidents, burns, shock - and certain maternal health conditions, such as postpartum hemorrhage.
CSL's commitment to growing its medicines production capacity is expected to create at least 300 new pharmaceutical roles and approximately 800 construction and related jobs in the local community.
Currently, more than 1,200 full-time employees work at the Kankakee site. Since 2018, CSL has invested more than $3 billion in its U.S. operations, creating over 6,500 new American jobs and bringing its total U.S. headcount to nearly 19,000, representing about 60% of CSL's global workforce.
